Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Additionally, over 53% of biotech firms are exploring next-generation GLP-1 analogs, enhancing future growth potential across the GLP-1 Drug Market
Notably, SURMOUNT-1, which excluded patients with diabetes, showed improvements with tirzepatide in all prespecified cardiometabolic measures
2.4 Assessment of anthropometric and biochemical parameters At baseline (timepoint 1), at the end of semaglutide intervention (timepoint 2), and at the end of the study (timepoint 3), all participants underwent body weight assessment
Emerging multi-agonists such as retatrutide (GLP-1/GIP/glucagon triple agonist) and PTT-A (novel unimolecular peptide tetra-agonist targeting GLP-1, GIP, glucagon and amylin receptors) further expand this concept
US$ 24.06
US$ 20.47
US$ 29.76
US$ 24.00
US$ 26.00
US$ 21.12
US$ 22.85
